The Palpable Prostate

Prostate cancer topics, links and more. Now at 100+ posts!

News: Health Day, Medical News Today, ScienceDaily, Urol Times, Urotoday, Zero Cancer Papers: Pubmed (all), Pubmed (Free only), Amedeo
Journals: Eur Urol, J Urol, JCO, The Prostate Others Pubmed Central Journals (Free): Adv Urol, BMC Urol, J Endourol, Kor J Urol, Rev Urol, Ther Adv Urol, Urol Ann
Reviews: Cochrane Summaries, PC Infolink Newsletters: PCRI, US Too General Medical Reviews: f1000, Health News Review
Loading...

Tuesday, April 1, 2014

Updates for March 2014

March 13, 2014. Under Benchmarking to the right we added a link to the US Senate subcommittee hearing on Health Care in Other Countries: http://www.help.senate.gov//hearings/hearing/?id=8acab996-5056-a032-522e-e39ca45fcfbe

Friday, February 28, 2014

Updates for February 2014

In Advice to the Newly Diagnosed we added:
2014 Swedish Study. An observational study of 34,515 men over 15 years (from 1996 to 2010) found that for men with metastatic prostate cancer survival was similar among the surgery and radiation groups; however, for men with non-metastatic prostate cancer survival was better among patients who had surgery relative to those who had had radiation (particularly among younger and healthier men). This is summarized in Fig. 2. [PMID: 24574496] [Full free text].

Thursday, January 30, 2014

Updates for January 2014

Jan 25, 2014. In Biochemical PSA Recurrence we added: Itraconazole. A 2013 John Hopkins study found that among 29 men with of metastatic castration-resistant prostate cancer taking 600 mg/day of the drug itraconazole (which is currently approved in the US as an antifungal and is also known as Onmel® or Sporanox®) resulted in no PSA progression in 14 of 29 high dose subjects at 24 weeks. The high dosage seems essential as among 17 men in a low dose arm (200 mg/day) it was found to be ineffective and that part of the study terminated early. This and previous test tube and animal studies (see references 11-16 in paper) found that the mechanism of action is to inhibit angiogenesis and Hedgehog signaling. The researchers concluded that the high dose regimen has "has modest antitumor activity". Side effects included fatigue, nausea, anorexia, rash, and a syndrome of hypokalemia, hypertension, and edema. Additional side effects are listed here. There are a number of drugs which should not be taken with Itraconazole. See Wikipedia. The abstract and full paper are available here: [PMID: 23340005] [Full paper].

Saturday, November 30, 2013

Updates for November 2013

November 30, 2103. A new link on the right hand side to the Commonwealth Report comparing 11 countries' health care systems appears on the Benchmarking line.

Thursday, October 31, 2013

Updates for October 2013

Oct 31, 2013. In Biochemical PSA Recurrence we added: Ornish Lifestyle Study. A pilot study published in the Lancet of prostate cancer patients conducted in the lab of Nobel laureate Elizabeth H. Blackburn, by Dean Ornish and others at UCSF found that life style changes were associated with increase telomere length (a measure of aging - longer is more favorable). Article and Ornish interview video. A bit more detail on the life style changes (from the Toronto Star) is here. NPR article cautions that telomeres are not the whole story and even the favorability of longer telomeres is not certain: NPR article The abstract to the study is here: [pubmed: 24051140]

Saturday, September 28, 2013

Updates for September 2013

Sep 27, 2013. In Prostate Cancer Calculators we added: The Kaiser Foundation Calculator estimates how much you will have to pay for mandatory US health care insurance based on income, state, etc. [Calculator]
Sep 22, 2013. In Advice to the Newly Diagnosed we added: See this localized prostate cancer video, this locally advanced cancer video and this metastatic disease video and other videos at the site. The site author also has recently published the second edition of Winning the Battle Against Prostate Cancer.